Specialty Drug

Key facts

Legal definition

None that applies uniformly across payers

Medicare Part D

Specialty tier limited to drugs above a CMS-set monthly cost threshold

Common channel

Specialty pharmacies, often in limited distribution networks

Typical examples

Biologics for autoimmune disease, oral cancer drugs, hepatitis C antivirals

What is a specialty drug?

Specialty is a benefit management category, not a scientific or FDA classification. A drug is usually labeled specialty when it combines several traits: high cost, a complex or rare condition, injection or infusion, special storage such as refrigeration, close clinical monitoring, or restricted distribution.

Many specialty drugs are biologics, but not all. Oral cancer drugs, hepatitis C antivirals and some multiple sclerosis tablets are small molecules that payers still manage as specialty products.

How specialty drugs are defined and managed

Each part of the system draws the specialty line in its own way:

• Medicare Part D: plans may place a drug on a specialty tier only if its negotiated monthly cost exceeds a threshold that the Centers for Medicare and Medicaid Services (CMS) sets and updates, and plans may deny tiering exceptions for drugs on that tier.
• Commercial plans and pharmacy benefit managers (PBMs): each maintains its own specialty drug list, usually based on cost plus handling and monitoring needs.
• Distribution: manufacturers often limit dispensing to a small network of specialty pharmacies, sometimes to meet a Risk Evaluation and Mitigation Strategy (REMS) or to collect patient data.
• Benefit channel: self-administered specialty drugs usually fall under the pharmacy benefit, while clinic-administered ones usually fall under the medical benefit.
• Utilization management: prior authorization, step therapy and site-of-care rules are common.

Why specialty drugs matter

Specialty status shapes spending, access and data visibility:

• Spending concentration: specialty drugs make up a small share of prescriptions but a large and growing share of drug spending in both Medicare and commercial plans.
• Channel strategy: manufacturer choices of specialty pharmacy networks and patient hub services determine how patients start therapy and which transactions appear in pharmacy data.
• Patient cost exposure: specialty tiers often use coinsurance rather than flat copays, which affects adherence and the use of copay assistance programs.
• Data comparability: because each payer defines specialty differently, a specialty flag in one dataset may not match another, so compare cost, route and distribution attributes instead.